Engineered RNA Modification Recognition

工程化 RNA 修饰识别

• 批准号: 10697237
• 负责人: Zachary Miles
• 金额: $ 34.77万
• 依托单位: ALIDA BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2023-10-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10697237
• 关键词: Acceleration; Affinity; Aging; Alternative Splicing; Antibodies; Award; Bar Codes; Binding; Bioinformatics; Biological; Biological Assay; Biological Sciences; Biology; Biopsy; Cells; Chemicals; Chemotherapy-Oncologic Procedure; Clinical; Clinical Trials; Code; Coupled; DNA; Dedications; Dependence; Detection; Directed Molecular Evolution; Disease; Disease Progression; Drug resistance; Elements; Engineering; Evolution; Exhibits; Funding; Gene Expression; Genetic Code; Genetic Transcription; Grant; Health; Knowledge; Libraries; Ligands; Malignant Neoplasms; Messenger RNA; Methods; Modification; Molecular; Mutation; Needle biopsy procedure; Outcome; Pathway interactions; Performance; Phase; Play; Process; Property; Protein Engineering; Proteins; Publications; RNA; RNA Folding; RNA Sequences; RNA-Protein Interaction; Reader; Reading; Reagent; Regulator Genes; Reproducibility; Research; Research Personnel; Role; Sampling; Science; Small Business Innovation Research Grant; Specificity; Technology; Testing; Therapeutic; Time; Transcript; Translations; Variant; Vertebral column; Virus Diseases; Work; Yeasts; clinical biomarkers; clinically relevant; cloud based; commercialization; data handling; design; diagnostic biomarker; drug development; epitranscriptome; epitranscriptomics; improved; molecular recognition; monomer; nano; next generation; novel; novel diagnostics; nucleobase; product development; programs; rapid growth; scaffold; success; symposium; technology platform; trafficking; tumor; tumor progression; user-friendly

Abstract Alida Biosciences Inc is developing a commercial platform for the analysis of the epitranscriptome, which is the totality of chemical modifications applied naturally to RNA to regulate possibly all aspects of RNA biology: transcription (mods are installed co-transcriptionally), translation, transcript lifetime, trafficking, alternative splicing, RNA folding, RNA–protein interactions, and more. The field of epitranscriptomics has seen rapid growth, motivated by the significance of this biology and the emerging opportunities to use RNA modifications as diagnostic biomarkers and to intervene in epitranscriptomic pathways as a promising novel paradigm in drug development, especially in cancer chemotherapy. Alida’s platform technology will make epitranscriptomics more accessible by offering a user-friendly workflow, integrated process controls, and cloud-based data handling and bioinformatics. In this SBIR grant, we seek to develop engineered RNA modification binding agents for integration into our platform. The enhanced properties of the novel agents will be optimized specifically for our platform to maximize sensitivity and selectivity, which is especially significant for high-value clinical samples in which only sub-nanogram quantities of RNA are likely to be available: needle biopsies, FFPE samples, and others.

摘要